loading page

Roflumilast Ameliorates Diabetic Nephropathy in Rats Through Down-Regulation of JAK/STAT Signaling Pathway
  • +2
  • Sandip Patel,
  • Priyal Patel,
  • Piyush Chudasama,
  • Shailesh Soni,
  • Manan Raval A
Sandip Patel
LM College of Pharmacy

Corresponding Author:[email protected]

Author Profile
Priyal Patel
Ramanbhai Patel College of Pharmacy
Author Profile
Piyush Chudasama
Sat-Kaival Hospital Pvt Ltd
Author Profile
Shailesh Soni
Muljibhai Patel Urological Hospital
Author Profile
Manan Raval A
Ramanbhai Patel College of Pharmacy
Author Profile


Diabetes nephropathy (DN) is one of the most prevalent microvascular complications of Diabetes Mellitus (DM). The present study was carried out to explore the role of roflumilast, a PDE4 inhibitor, as a potential treatment option for DN. The model was developed by feeding a high-fat diet for four weeks and following streptozotocin (30 mg/kg) injection intraperitoneally. The rats with >13.8 mmol/L blood glucose were included in the study. The diabetic rats were treated with roflumilast (0.25, 0.5, 1 mg/kg) and standard metformin (100 mg/kg) orally once a day for eight weeks. Roflumilast (1 mg/kg) remarkably improved renal damage, which was indicated by an increase in 16% albumin, a decrease in 5% serum creatinine, 12% BUN, 19% HbA1c, and 34% blood glucose. It also significantly improves the oxidative stress levels, which was indicated by a decrease in 18% MDA level and an increase in GSH, SOD, and catalase by 6%, 4%, and 5%, respectively. Roflumilast (1 mg/kg) decreased the HOMA-IR index by 28% and increased the pancreatic β-cells functioning by 30%. Moreover, significant improvement in histopathological abnormalities was observed in roflumilast treatment groups. Roflumilast treatment was shown to down-regulate the gene expression of TNF-α, NF-kB, MCP-1, fibronectin, and collagen IV, and upregulated the expression of the Nrf2 gene. The gene expression was significantly reduced by 2.1-fold, 2.3-fold, 2.5-fold, 2.7-fold, and 1.52-fold individually. The Nrf2 gene was upregulated by 1.43-fold. These results manifested that roflumilast alleviated renal injuries in DN rats, which might be associated with suppressing the JAK/STAT signaling pathway.